Sanofi SA to Discuss Phase 2b Results Of The Investigational BTK Inhibitor ('168) In Relapsing Multiple Sclerosis Conference Call Transcript
Good morning and good afternoon to everyone on the call. I hope everyone is safe and remaining healthy. Thank you for joining us to review the Phase II results of our brain-penetrant BTK inhibitor '168. As usual, you can find the slides to this call on the Investors page of our website at sanofi.com.
Moving to Slide 2. I would like to remind you that information presented in this call contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d'Enregistrement Universel for a description of these risk factors.
With that, please advance to Slide 3. Our speakers today in the order of presenting are Bill Sibold, Executive Vice President, Specialty Care; Erik Wallström, Therapeutic Area Head, Neurology Development; Rita Balice-Gordon, Therapeutic Area Head, Neurologic and Rare Disease Research; and John Reed, Executive Vice President, Global Head of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
